CN102007209A - 细小病毒rep和cap蛋白在昆虫细胞中的表达优化 - Google Patents
细小病毒rep和cap蛋白在昆虫细胞中的表达优化 Download PDFInfo
- Publication number
- CN102007209A CN102007209A CN2009801135713A CN200980113571A CN102007209A CN 102007209 A CN102007209 A CN 102007209A CN 2009801135713 A CN2009801135713 A CN 2009801135713A CN 200980113571 A CN200980113571 A CN 200980113571A CN 102007209 A CN102007209 A CN 102007209A
- Authority
- CN
- China
- Prior art keywords
- promotor
- nucleotide sequence
- rep
- parvovirus
- coding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14211—Erythrovirus, e.g. B19 virus
- C12N2750/14241—Use of virus, viral particle or viral elements as a vector
- C12N2750/14243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/103—Plasmid DNA for invertebrates
- C12N2800/105—Plasmid DNA for invertebrates for insects
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/50—Vectors for producing vectors
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (15)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2967308P | 2008-02-19 | 2008-02-19 | |
US61/029,673 | 2008-02-19 | ||
EP08151634.6 | 2008-02-19 | ||
EP08151634 | 2008-02-19 | ||
PCT/NL2009/050076 WO2009104964A1 (en) | 2008-02-19 | 2009-02-19 | Optimisation of expression of parvoviral rep and cap proteins in insect cells |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102007209A true CN102007209A (zh) | 2011-04-06 |
CN102007209B CN102007209B (zh) | 2013-11-13 |
Family
ID=39386462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009801135713A Active CN102007209B (zh) | 2008-02-19 | 2009-02-19 | 细小病毒rep和cap蛋白在昆虫细胞中的表达优化 |
Country Status (10)
Country | Link |
---|---|
US (2) | US8642314B2 (zh) |
EP (2) | EP2250256B1 (zh) |
JP (1) | JP2011512156A (zh) |
CN (1) | CN102007209B (zh) |
AU (1) | AU2009215987B2 (zh) |
CA (1) | CA2715924C (zh) |
EA (1) | EA020969B1 (zh) |
ES (2) | ES2929031T3 (zh) |
IL (1) | IL207671A (zh) |
WO (1) | WO2009104964A1 (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102492692A (zh) * | 2011-12-16 | 2012-06-13 | 西南大学 | 增强子Hr3 |
CN108699567A (zh) * | 2016-04-21 | 2018-10-23 | 威洛克有限公司 | 昆虫细胞中的aav产生、其方法和组合物 |
CN110177579A (zh) * | 2016-11-07 | 2019-08-27 | 星火治疗股份有限公司 | Rab保护蛋白效价测定 |
CN110551758A (zh) * | 2018-05-30 | 2019-12-10 | 中央研究院 | 重组杆状病毒及其用途 |
CN110964749A (zh) * | 2018-09-29 | 2020-04-07 | 普莱柯生物工程股份有限公司 | 一种在杆状病毒表达系统中高效表达外源蛋白的方法及其应用 |
CN111527201A (zh) * | 2017-12-29 | 2020-08-11 | 优尼科Ip有限公司 | 修饰的病毒载体及其制备和使用方法 |
CN114736928A (zh) * | 2022-05-16 | 2022-07-12 | 睿征医药科技(武汉)有限公司 | 一种杆状病毒载体及其在昆虫细胞中制备rAAV的应用 |
WO2023039936A1 (zh) * | 2021-09-18 | 2023-03-23 | 劲帆生物医药科技(武汉)有限公司 | 一种用于在昆虫细胞中表达包含重叠开放阅读框的基因的表达盒及其应用 |
WO2023221240A1 (zh) * | 2022-05-16 | 2023-11-23 | 睿征医药科技(武汉)有限公司 | 一种用于昆虫细胞中产生重组杆状病毒的组合物、方法及应用 |
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102007209B (zh) * | 2008-02-19 | 2013-11-13 | 阿姆斯特丹分子治疗(Amt)股份有限公司 | 细小病毒rep和cap蛋白在昆虫细胞中的表达优化 |
WO2011112089A2 (en) | 2010-03-11 | 2011-09-15 | Amsterdam Molecular Therapeutics (Amt) Ip B.V. | Mutated rep encoding sequences for use in aav production |
WO2011112090A2 (en) * | 2010-03-11 | 2011-09-15 | Amsterdam Molecular Therapeutics (Amt) Ip B.V. | Method for identifying variant rep protein encoding nucleic acids |
RS53344B (en) | 2010-09-02 | 2014-10-31 | Molmed Spa | STABLE PRODUCTION OF LENTIVIRUS VECTORS |
TWI775096B (zh) | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
SG10201703671SA (en) * | 2012-11-15 | 2017-08-30 | Nat Univ Singapore | Univariant extrinsic initiator control system for microbes and an in vitro assembly of large recombinant dna molecules from multiple components |
WO2015060722A1 (en) | 2013-10-24 | 2015-04-30 | Uniqure Ip B.V. | Aav-5 pseudotyped vector for gene therapy for neurological diseases |
SG10201810150UA (en) | 2014-03-17 | 2018-12-28 | Adverum Biotechnologies Inc | Compositions and methods for enhanced gene expression in cone cells |
WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
RU2020109343A (ru) | 2014-11-05 | 2020-03-17 | Вояджер Терапьютикс, Инк. | Полинуклеотиды aadc для лечения болезни паркинсона |
MX2017006216A (es) | 2014-11-14 | 2018-08-29 | Voyager Therapeutics Inc | Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela). |
DK3218386T3 (da) | 2014-11-14 | 2021-06-07 | Voyager Therapeutics Inc | Modulatorisk polynukleotid |
PL3224376T5 (pl) | 2014-11-28 | 2023-08-21 | Uniqure Ip B.V. | Zanieczyszczenia DNA w kompozycji zawierającej wiriony parwowirusowe |
EP3230441A4 (en) | 2014-12-12 | 2018-10-03 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
CA2971920C (en) | 2014-12-24 | 2024-05-07 | Uniqure Ip B.V. | Rnai induced huntingtin gene suppression |
WO2016141078A1 (en) | 2015-03-02 | 2016-09-09 | Avalanche Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
CA3006569A1 (en) | 2015-12-02 | 2017-06-08 | Voyager Therapeutics, Inc. | Assays for the detection of aav neutralizing antibodies |
GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
MX2018012663A (es) * | 2016-04-16 | 2019-07-08 | Univ Florida | Metodos para aumentar la capacidad de actividad biológica del virus adenoasociado recombinante producido mediante el sistema baculovirus. |
US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
IL302748A (en) | 2016-05-18 | 2023-07-01 | Voyager Therapeutics Inc | modulatory polynucleotides |
CN109831916B (zh) | 2016-05-18 | 2023-07-21 | 沃雅戈治疗公司 | 治疗亨廷顿氏舞蹈病的组合物和方法 |
EP3831281A1 (en) | 2016-08-30 | 2021-06-09 | The Regents of The University of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
US10286087B2 (en) | 2016-12-16 | 2019-05-14 | Uniqure Ip B.V. | Immunoadsorption |
US11752181B2 (en) | 2017-05-05 | 2023-09-12 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's disease |
CN110913866A (zh) | 2017-05-05 | 2020-03-24 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
EP3652326A1 (en) | 2017-07-10 | 2020-05-20 | uniQure IP B.V. | Means and methods for aav gene therapy in humans |
WO2019018342A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | NETWORK EQUIPMENT TRACK GUIDE SYSTEM |
EP3662060A2 (en) | 2017-08-03 | 2020-06-10 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
EP3688014A4 (en) | 2017-09-29 | 2020-09-16 | Massachusetts Eye and Ear Infirmary | PRODUCTION OF ADENO-ASSOCIATED VIRUSES IN INSECT CELLS |
US20200237799A1 (en) | 2017-10-16 | 2020-07-30 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
JP7502991B2 (ja) | 2017-10-16 | 2024-06-19 | ボイジャー セラピューティクス インコーポレイテッド | 筋萎縮性側索硬化症(als)の治療 |
BR112020014625A2 (pt) | 2018-01-17 | 2020-12-08 | Meiragtx Uk Ii Limited | Proteína de capsídeo de raav modificada para terapia gênica |
EP3788165A1 (en) | 2018-04-29 | 2021-03-10 | REGENXBIO Inc. | Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles |
WO2019212921A1 (en) | 2018-04-29 | 2019-11-07 | Regenxbio Inc. | Scalable clarification process for recombinant aav production |
EP3807404A1 (en) | 2018-06-13 | 2021-04-21 | Voyager Therapeutics, Inc. | Engineered 5' untranslated regions (5' utr) for aav production |
EP3807405A2 (en) | 2018-06-14 | 2021-04-21 | REGENXBIO Inc. | Anion exchange chromatography for recombinant aav production |
US20210355454A1 (en) | 2018-07-24 | 2021-11-18 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
CN112567027A (zh) | 2018-08-10 | 2021-03-26 | 再生生物股份有限公司 | 用于重组aav生产的可扩展方法 |
EP3850098A1 (en) | 2018-09-12 | 2021-07-21 | uniQure IP B.V. | Rnai induced c9orf72 suppression for the treatment of als/ftd |
TW202035689A (zh) | 2018-10-04 | 2020-10-01 | 美商航海家醫療公司 | 測量病毒載體粒子的效價及強度之方法 |
CA3115248A1 (en) | 2018-10-05 | 2020-04-09 | Voyager Therapeutics, Inc. | Engineered nucleic acid constructs encoding aav production proteins |
CN113166781A (zh) * | 2018-10-15 | 2021-07-23 | 沃雅戈治疗公司 | 在杆状病毒/Sf9系统中大规模生产rAAV的表达载体 |
US20210324483A1 (en) | 2018-10-15 | 2021-10-21 | Regenxbio Inc. | Method for measuring the infectivity of replication defective viral vectors and viruses |
US11702673B2 (en) | 2018-10-18 | 2023-07-18 | University Of Florida Research Foundation, Incorporated | Methods of enhancing biological potency of baculovirus system-produced recombinant adeno-associated virus |
WO2020104480A1 (en) | 2018-11-19 | 2020-05-28 | Uniqure Biopharma B.V. | Adeno-associated virus vectors for expressing fviii mimetics and uses thereof |
WO2020104469A1 (en) | 2018-11-19 | 2020-05-28 | Uniqure Ip B.V. | Method and means to deliver mirna to target cells |
CA3119721A1 (en) | 2018-11-19 | 2020-05-28 | Uniqure Ip B.V. | A companion diagnostic to monitor the effects of gene therapy |
AU2019385598A1 (en) | 2018-11-19 | 2021-06-03 | Uniqure Ip B.V. | RNAi induced reduction of ataxin-3 for the treatment of Spinocerebellar ataxia type 3 |
AU2020208467A1 (en) | 2019-01-18 | 2021-08-05 | Voyager Therapeutics, Inc. | Methods and systems for producing AAV particles |
CN113728108A (zh) | 2019-02-15 | 2021-11-30 | 桑格摩生物治疗股份有限公司 | 用于生产重组aav的组合物和方法 |
TW202102526A (zh) | 2019-04-04 | 2021-01-16 | 美商銳進科斯生物股份有限公司 | 重組腺相關病毒及其用途 |
FI3953483T3 (fi) | 2019-04-11 | 2023-11-30 | Regenxbio Inc | Kokoekskluusiokromatografiamenetelmiä rekombinanttien adenoassosioituneiden viruskoostumusten karakterisoimiseksi |
TW202332458A (zh) | 2019-04-19 | 2023-08-16 | 美商銳進科斯生物股份有限公司 | 腺相關病毒載體調配物及方法 |
EP3959323A1 (en) | 2019-04-24 | 2022-03-02 | REGENXBIO Inc. | Fully-human post-translationally modified antibody therapeutics |
TW202106879A (zh) | 2019-04-29 | 2021-02-16 | 美商航海家醫療公司 | 於生物反應器中生產經桿狀病毒感染之昆蟲細胞(biic)之系統及方法 |
US20220251567A1 (en) | 2019-07-10 | 2022-08-11 | Inserm (Institut National De La Santè Et De La Recherche Médicale) | Methods for the treatment of epilepsy |
KR20220081971A (ko) | 2019-07-15 | 2022-06-16 | 메이라지티엑스 유케이 Ii 리미티드 | 관절염 질환 치료용 변형된 aav 캡시드 단백질 |
EP4004214A1 (en) | 2019-07-26 | 2022-06-01 | RegenxBio Inc. | Engineered nucleic acid regulatory element and methods of uses thereof |
WO2021030125A1 (en) | 2019-08-09 | 2021-02-18 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
WO2021041485A1 (en) | 2019-08-26 | 2021-03-04 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2021053018A1 (en) | 2019-09-16 | 2021-03-25 | Uniqure Ip B.V. | Targeting misspliced transcripts in genetic disorders |
WO2021099394A1 (en) | 2019-11-19 | 2021-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antisense oligonucleotides and their use for the treatment of cancer |
BR112022009895A2 (pt) | 2019-11-28 | 2022-08-09 | Regenxbio Inc | Construtos de terapia de gene de microdistrofina e usos dos mesmos |
KR20220110781A (ko) | 2019-12-04 | 2022-08-09 | 상가모 테라퓨틱스, 인코포레이티드 | 재조합 aav를 생산하기 위한 신규 조성물 및 방법 |
US20230160892A1 (en) * | 2020-03-24 | 2023-05-25 | Academia Sinica | Recombinant viruses, insect cells and their uses in viral detection and vaccination |
JP2023519138A (ja) | 2020-04-02 | 2023-05-10 | ユニキュアー バイオファーマ ビー.ブイ. | 新規細胞株 |
JP2023519502A (ja) | 2020-04-02 | 2023-05-11 | ユニキュアー バイオファーマ ビー.ブイ. | Aav生成のための二重二官能基ベクター |
CA3174872A1 (en) | 2020-04-07 | 2021-10-14 | Sander Jan Hendrik Van Deventer | Gene constructs for silencing angiopoietin-like 3 (angptl3) and uses thereof |
WO2022011262A1 (en) | 2020-07-10 | 2022-01-13 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating epilepsy |
EP4192514A1 (en) | 2020-08-06 | 2023-06-14 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
EP4213890A1 (en) | 2020-09-15 | 2023-07-26 | RegenxBio Inc. | Vectorized lanadelumab and administration thereof |
WO2022060916A1 (en) | 2020-09-15 | 2022-03-24 | Regenxbio Inc. | Vectorized antibodies for anti-viral therapy |
WO2022076711A2 (en) | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Adeno-associated viruses for ocular delivery of gene therapy |
WO2022076750A2 (en) | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Recombinant adeno-associated viruses for cns or muscle delivery |
WO2022094157A1 (en) | 2020-10-28 | 2022-05-05 | Regenxbio Inc. | Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof |
CA3195967A1 (en) | 2020-10-28 | 2022-05-05 | Xu Wang | Vectorized anti-tnf-? antibodies for ocular indications |
EP4236974A2 (en) | 2020-10-29 | 2023-09-06 | RegenxBio Inc. | Vectorized factor xii antibodies and administration thereof |
CA3196964A1 (en) | 2020-10-29 | 2022-05-05 | Xu Wang | Vectorized tnf-alpha antagonists for ocular indications |
AU2021403076A1 (en) | 2020-12-16 | 2023-06-29 | Regenxbio Inc. | Method of producing a recombinant adeno-associated virus particle |
TW202241943A (zh) | 2020-12-29 | 2022-11-01 | 美商銳進科斯生物股份有限公司 | Tau特異性抗體基因療法組合物、方法及其用途 |
CA3205209A1 (en) | 2021-01-21 | 2022-07-28 | Regenxbio Inc. | Improved production of recombinant polypeptides and viruses |
CN112852882A (zh) * | 2021-02-04 | 2021-05-28 | 中吉智药(南京)生物技术有限公司 | 一种杆状病毒感染昆虫细胞生产aav基因药物的系统及方法 |
US20240141378A1 (en) | 2021-03-03 | 2024-05-02 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
US20240141377A1 (en) | 2021-03-03 | 2024-05-02 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2022188797A1 (en) | 2021-03-09 | 2022-09-15 | Huigene Therapeutics Co., Ltd. | Engineered crispr/cas13 system and uses thereof |
EP4314258A1 (en) | 2021-04-02 | 2024-02-07 | uniQure biopharma B.V. | Methods for producing single insect cell clones |
WO2022214635A1 (en) | 2021-04-08 | 2022-10-13 | Stichting Vu | Nucleic acid molecules for compensation of stxbp1 haploinsufficiency and their use in the treatment of stxbp1-related disorders |
JP2024517143A (ja) | 2021-04-26 | 2024-04-19 | リジェネックスバイオ インコーポレイテッド | ジストロフィン異常症の治療のためのマイクロジストロフィン遺伝子療法投与 |
EP4334454A2 (en) | 2021-05-04 | 2024-03-13 | RegenxBio Inc. | Novel aav vectors and methods and uses thereof |
WO2022241030A1 (en) | 2021-05-11 | 2022-11-17 | Regenxbio Inc. | Treatment of duchenne muscular dystrophy and combinations thereof |
AU2022285138A1 (en) | 2021-06-02 | 2023-11-30 | Uniqure Biopharma B.V. | Adeno-associated virus vectors modified to bind high-density lipoprotein |
EP4359525A1 (en) | 2021-06-21 | 2024-05-01 | uniQure biopharma B.V. | Gene constructs for silencing alpha-synuclein and uses thereof |
EP4359010A1 (en) | 2021-06-21 | 2024-05-01 | uniQure biopharma B.V. | Improved lysis procedures |
WO2023283962A1 (en) | 2021-07-16 | 2023-01-19 | Huigene Therapeutics Co., Ltd. | Modified aav capsid for gene therapy and methods thereof |
EP4373947A1 (en) | 2021-07-19 | 2024-05-29 | New York University | Auf1 combination therapies for treatment of muscle degenerative disease |
EP4392434A1 (en) * | 2021-08-26 | 2024-07-03 | uniQure biopharma B.V. | Insect cell-produced high potency aav vectors with cns-tropism |
CN118202060A (zh) | 2021-10-05 | 2024-06-14 | 再生生物股份有限公司 | 用于重组aav生产的组合物和方法 |
WO2023060113A1 (en) | 2021-10-05 | 2023-04-13 | Regenxbio Inc. | Compositions and methods for recombinant aav production |
WO2023060269A1 (en) | 2021-10-07 | 2023-04-13 | Regenxbio Inc. | Recombinant adeno-associated viruses for targeted delivery |
WO2023060272A2 (en) | 2021-10-07 | 2023-04-13 | Regenxbio Inc. | Recombinant adeno-associated viruses for cns tropic delivery |
WO2023077092A1 (en) | 2021-10-28 | 2023-05-04 | Regenxbio Inc. | Engineered nucleic acid regulatory elements and methods and uses thereof |
WO2023147374A2 (en) | 2022-01-25 | 2023-08-03 | Voyager Therapeutics, Inc. | Baculovirus expression system |
WO2023178053A1 (en) | 2022-03-13 | 2023-09-21 | Regenxbio Inc. | Modified muscle-specific promoters |
WO2023183623A1 (en) | 2022-03-25 | 2023-09-28 | Regenxbio Inc. | Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy |
WO2023201207A1 (en) | 2022-04-11 | 2023-10-19 | Tenaya Therapeutics, Inc. | Adeno-associated virus with engineered capsid |
WO2023198745A1 (en) | 2022-04-12 | 2023-10-19 | Uniqure Biopharma B.V. | Nucleic acid regulation of apoe |
WO2023198663A1 (en) | 2022-04-12 | 2023-10-19 | Uniqure Biopharma B.V. | Nucleic acid regulation of snca |
WO2023198662A1 (en) | 2022-04-12 | 2023-10-19 | Uniqure Biopharma B.V. | Novel systems for nucleic acid regulation |
WO2023198702A1 (en) | 2022-04-12 | 2023-10-19 | Uniqure Biopharma B.V. | Nucleic acid regulation of c9orf72 |
WO2023201277A1 (en) | 2022-04-14 | 2023-10-19 | Regenxbio Inc. | Recombinant adeno-associated viruses for cns tropic delivery |
TW202400803A (zh) | 2022-05-03 | 2024-01-01 | 美商銳進科斯生物股份有限公司 | 載體化抗補體抗體與補體劑及其投與 |
WO2023215807A1 (en) | 2022-05-03 | 2023-11-09 | Regenxbio Inc. | VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS |
WO2023239627A2 (en) | 2022-06-08 | 2023-12-14 | Regenxbio Inc. | Methods for recombinant aav production |
WO2024017990A1 (en) | 2022-07-21 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Methods and compositions for treating chronic pain disorders |
WO2024044725A2 (en) | 2022-08-24 | 2024-02-29 | Regenxbio Inc. | Recombinant adeno-associated viruses and uses thereof |
WO2024054983A1 (en) | 2022-09-08 | 2024-03-14 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2024081746A2 (en) | 2022-10-11 | 2024-04-18 | Regenxbio Inc. | Engineered nucleic acid regulatory elements and methods and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6723551B2 (en) * | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
US7271002B2 (en) * | 2001-11-09 | 2007-09-18 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
SI1945779T1 (sl) * | 2005-10-20 | 2013-07-31 | Uniqure Ip B.V. | Izboljĺ ani aav vektorji proizvedeni v celicah insekta |
US20090191597A1 (en) * | 2006-01-20 | 2009-07-30 | Asklepios Biopharmaceutical, Inc. | Enhanced production of infectious parvovirus vectors in insect cells |
CN103849629B (zh) * | 2006-06-21 | 2017-06-09 | 尤尼克尔Ip股份有限公司 | 具有经修饰的用于在昆虫细胞中产生aav的aav‑rep78翻译起始密码子的载体 |
US8945918B2 (en) * | 2006-08-24 | 2015-02-03 | Virovek, Inc. | Expression in insect cells of genes with overlapping open reading frames, methods and compositions therefor |
CN102007209B (zh) * | 2008-02-19 | 2013-11-13 | 阿姆斯特丹分子治疗(Amt)股份有限公司 | 细小病毒rep和cap蛋白在昆虫细胞中的表达优化 |
-
2009
- 2009-02-19 CN CN2009801135713A patent/CN102007209B/zh active Active
- 2009-02-19 CA CA2715924A patent/CA2715924C/en active Active
- 2009-02-19 US US12/918,460 patent/US8642314B2/en active Active
- 2009-02-19 JP JP2010547582A patent/JP2011512156A/ja active Pending
- 2009-02-19 EP EP09713345.8A patent/EP2250256B1/en active Active
- 2009-02-19 WO PCT/NL2009/050076 patent/WO2009104964A1/en active Application Filing
- 2009-02-19 AU AU2009215987A patent/AU2009215987B2/en active Active
- 2009-02-19 EP EP17181630.9A patent/EP3257937B1/en active Active
- 2009-02-19 ES ES17181630T patent/ES2929031T3/es active Active
- 2009-02-19 ES ES09713345.8T patent/ES2644880T3/es active Active
- 2009-02-19 EA EA201070970A patent/EA020969B1/ru not_active IP Right Cessation
-
2010
- 2010-08-18 IL IL207671A patent/IL207671A/en active IP Right Grant
-
2014
- 2014-01-08 US US14/149,953 patent/US9260724B2/en active Active
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102492692A (zh) * | 2011-12-16 | 2012-06-13 | 西南大学 | 增强子Hr3 |
CN102492692B (zh) * | 2011-12-16 | 2013-07-10 | 西南大学 | 增强子Hr3 |
CN108699567A (zh) * | 2016-04-21 | 2018-10-23 | 威洛克有限公司 | 昆虫细胞中的aav产生、其方法和组合物 |
CN108699567B (zh) * | 2016-04-21 | 2024-02-13 | 威洛克有限公司 | 昆虫细胞中的aav产生、其方法和组合物 |
US11414676B2 (en) | 2016-04-21 | 2022-08-16 | Virovek, Inc. | AAV production in insect cells, methods and compositions therefor |
CN110177579A (zh) * | 2016-11-07 | 2019-08-27 | 星火治疗股份有限公司 | Rab保护蛋白效价测定 |
CN111527201A (zh) * | 2017-12-29 | 2020-08-11 | 优尼科Ip有限公司 | 修饰的病毒载体及其制备和使用方法 |
CN110551758B (zh) * | 2018-05-30 | 2024-02-06 | 中原大学 | 重组杆状病毒及其用途 |
CN110551758A (zh) * | 2018-05-30 | 2019-12-10 | 中央研究院 | 重组杆状病毒及其用途 |
CN110964749A (zh) * | 2018-09-29 | 2020-04-07 | 普莱柯生物工程股份有限公司 | 一种在杆状病毒表达系统中高效表达外源蛋白的方法及其应用 |
WO2023039936A1 (zh) * | 2021-09-18 | 2023-03-23 | 劲帆生物医药科技(武汉)有限公司 | 一种用于在昆虫细胞中表达包含重叠开放阅读框的基因的表达盒及其应用 |
CN114736928A (zh) * | 2022-05-16 | 2022-07-12 | 睿征医药科技(武汉)有限公司 | 一种杆状病毒载体及其在昆虫细胞中制备rAAV的应用 |
CN114736928B (zh) * | 2022-05-16 | 2023-06-27 | 睿征医药科技(武汉)有限公司 | 一种杆状病毒载体及其在昆虫细胞中制备rAAV的应用 |
WO2023221240A1 (zh) * | 2022-05-16 | 2023-11-23 | 睿征医药科技(武汉)有限公司 | 一种用于昆虫细胞中产生重组杆状病毒的组合物、方法及应用 |
WO2023221241A1 (zh) * | 2022-05-16 | 2023-11-23 | 睿征医药科技(武汉)有限公司 | 一种杆状病毒载体及其在昆虫细胞中制备rAAV的应用 |
Also Published As
Publication number | Publication date |
---|---|
JP2011512156A (ja) | 2011-04-21 |
CN102007209B (zh) | 2013-11-13 |
IL207671A (en) | 2015-04-30 |
ES2644880T3 (es) | 2017-11-30 |
EA020969B1 (ru) | 2015-03-31 |
CA2715924A1 (en) | 2009-08-27 |
US20110136227A1 (en) | 2011-06-09 |
EP2250256B1 (en) | 2017-08-02 |
ES2929031T3 (es) | 2022-11-24 |
EP3257937A1 (en) | 2017-12-20 |
US8642314B2 (en) | 2014-02-04 |
EP2250256A1 (en) | 2010-11-17 |
EA201070970A1 (ru) | 2011-02-28 |
CA2715924C (en) | 2021-01-12 |
AU2009215987B2 (en) | 2015-01-22 |
US20140127801A1 (en) | 2014-05-08 |
WO2009104964A1 (en) | 2009-08-27 |
IL207671A0 (en) | 2010-12-30 |
EP3257937B1 (en) | 2022-08-03 |
AU2009215987A1 (en) | 2009-08-27 |
US9260724B2 (en) | 2016-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102007209B (zh) | 细小病毒rep和cap蛋白在昆虫细胞中的表达优化 | |
US9988645B2 (en) | Vectors with modified initiation codon for the translation of AAV-REP78 useful for production of AAV | |
CN101287837B (zh) | 昆虫细胞中生产的改进的aav载体 | |
CN101868547B (zh) | 包含具有差别密码子偏性的重复编码序列的杆状病毒载体 | |
DK2035564T3 (en) | VECTORS WITH MODIFIED initiation codon TO THE TRANSLATION OF AAV rep 78 FOR PRODUCTION OF AAV IN INSECT CELLS | |
AU2014201171B2 (en) | Baculoviral vectors comprising repeated coding sequences with differential codon biases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: JURNIKL BIOPHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: AMSTERDAM MOLECULAR THERAPEUTICS BV |
|
CP01 | Change in the name or title of a patent holder |
Address after: Amsterdam Patentee after: UNIQURE IP B.V. Address before: Amsterdam Patentee before: Amsterdam Molecular Therapeutics BV |
|
ASS | Succession or assignment of patent right |
Owner name: UNIQURE IP B. V. Free format text: FORMER OWNER: JURNIKL BIOPHARMACEUTICAL CO., LTD. Effective date: 20150616 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150616 Address after: Amsterdam Patentee after: UNIQURE IP B.V. Address before: Amsterdam Patentee before: UNIQURE IP B.V. |